G250: a carbonic anhydrase IX monoclonal antibody.
G250 or carbonic anhydrase IX (CA IX) is a membrane-associated carbonic anhydrase (CA) thought to play a role in the regulation of cell proliferation in response to hypoxic conditions and may be involved in oncogenesis and tumor progression. G250 refers to a monoclonal antibody (mAb) that was raised by immunization of mice with human renal cell carcinoma (RCC) homogenates. The RCC-associated transmembrane protein designated G250 has since proven to be identical to tumor-associated protein MN or CA IX. Previous studies using a mAb against CA IX have shown that CA IX is induced constitutively in certain tumor types, but is absent in most normal tissues with the exception of epithelial cells of the gastric mucosa. Furthermore, previous immunobiochemical studies of malignant and benign renal tissues revealed that CA IX was also highly expressed in RCC. Studies on tumor-bearing kidneys demonstrate selective uptake of mAb CA IX in antigen-positive cells versus antigen-negative cells. Furthermore, extraordinarily high uptake and the requirement of a low protein dose to obtain tumor saturation with respect to tumor targeting occur with mAb CA IX. These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC.
Lam
John S
JS
Department of Medicine, David Geffen School of Medicine at UCLA, 2333 Peter Ueberroth Building, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA.
Pantuck
Allan J
AJ
Belldegrun
Arie S
AS
Figlin
Robert A
RA
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000276:immunology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D007680:Kidney Neoplasms / Q000178:diet therapy / Q000276:immunology*; D051379:Mice; D016499:Radioimmunotherapy; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C106533:G250 monoclonal antibody; D011993:Recombinant Fusion Proteins; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases
Cancer Immunol Immunother. 2002 May;51(3):171-7
11941456
Gastroenterology. 1997 Feb;112(2):398-408
9024293
N Engl J Med. 2001 Dec 6;345(23 ):1655-9
11759643
Cancer Res. 2000 Dec 15;60(24):7075-83
11156414
Int J Cancer. 1991 Jul 9;48(5):738-43
1830033
Cancer Res. 1990 Feb 1;50(3 Suppl):814s-819s
2404582
Anticancer Res. 1999 Mar-Apr;19(2A):1197-200
10368675
J Clin Oncol. 1993 Apr;11(4):738-50
8478666
Am J Pathol. 2001 Mar;158(3):905-19
11238039
Clin Cancer Res. 1999 Oct;5(10 Suppl):3268s-3274s
10541374
Cancer. 1997 Dec 15;80(12 Suppl):2390-7
9406688
Proc Natl Acad Sci U S A. 1985 May;82(9):2955-9
3857626
Cancer Res. 1999 Apr 1;59(7):1615-9
10197637
Lancet. 2001 Sep 22;358(9286):966-70
11583750
Urol Clin North Am. 2003 Nov;30(4):843-52
14680319
J Nucl Med. 2004 Aug;45(8):1412-21
15299069
Urol Clin North Am. 2003 Aug;30(3):623-31
12953760
Cancer Res. 1997 Jul 15;57(14 ):2827-31
9230182
Int J Cancer. 2000 Mar 15;85(6):865-70
10709109
Cell Cycle. 2004 Feb;3(2):164-7
14712082
J Clin Oncol. 1997 Apr;15(4):1529-37
9193349
Int J Cancer. 1994 Jan 15;56(2):262-8
8314310
J Nucl Med. 2004 Feb;45(2):327-37
14960657
Cancer Res. 2001 Sep 1;61(17 ):6394-9
11522632
Int J Cancer. 1986 Oct 15;38(4):489-94
2428759
Nat Rev Cancer. 2002 Jan;2(1):38-47
11902584
Br J Cancer. 2004 Mar 8;90(5):985-90
14997194
J Urol. 2002 Dec;168(6):2615-23
12441996
Cancer Res. 1985 Dec;45(12 Pt 1):6131-9
3904980
J Exp Med. 1979 Sep 19;150(3):564-79
479762
Clin Cancer Res. 2003 Feb;9(2):802-11
12576453
J Urol. 2000 Feb;163(2):408-17
10647643
J Urol. 1999 Feb;161(2):381-6; discussion 386-7
9915408
J Urol. 2001 Nov;166(5):1611-23
11586189
Cancer Biother Radiopharm. 1998 Apr;13(2):133-9
10850349
Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601
9770531
Clin Cancer Res. 1998 Nov;4(11):2729-39
9829736
Nature. 1975 Aug 7;256(5517):495-7
1172191
N Engl J Med. 2001 Dec 6;345(23 ):1711-2
11759660
Gastroenterology. 2002 Dec;123(6):1889-903
12454846
Oncogene. 2004 Jul 22;23 (33):5624-31
15184875
Immunol Rev. 1999 Aug;170:85-100
10566144
Oncogene. 1994 Oct;9(10 ):2877-88
8084592
Trends Mol Med. 2002;8(4 Suppl):S62-7
11927290
Science. 2001 Jul 13;293(5528):251-3
11452115
Genomics. 1996 May 1;33(3):480-7
8661007
J Nucl Med. 1988 Jun;29(6):1078-82
3373316